Klotho and Turn allow Letter of Intent to expire

Klotho Neurosciences (KLTO)announced that its Letter of Intent, or LoI, with Turn Biotechnologies was allowed to expire by the parties. Following careful evaluation, Klotho’s Board of Directors determined that the proposed transaction did not fit its long-term strategic plan. Instead, the Company will focus its resources on advancing its Klotho anti-aging protein research pipeline and development of treatments, where it sees the greatest opportunity to deliver value for patients and shareholders.